Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases.
Journal: Expert opinion on investigational drugs
Published: February 26, 2025
Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: June 02, 2024
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Journal: Pediatric blood & cancer
Published: October 27, 2023
Use of poxvirus display to select antibodies specific for complex membrane antigens.
Journal: mAbs
Published: August 28, 2023
Conclusions of the SIGNAL study in Huntington and implications for treatment of other slowly progressive neurodegenerative diseases.
Journal: Clinical and translational medicine
Published: December 22, 2022
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Journal: Nature medicine
Published: October 04, 2022
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity.
Journal: Journal of neuroinflammation
Published: November 04, 2021
Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model.
Journal: International journal of molecular sciences
Published: July 22, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 18, 2020
Last Updated: 09/26/2026